Literature DB >> 27563148

JAK2 V617F clonal disorders: fate or chance?

George S Vassiliou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27563148      PMCID： PMC5305049          DOI： 10.1182/blood-2016-07-726448

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Aging as a driver of leukemogenesis.

Authors:  Thomas McKerrell; George S Vassiliou
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

2.  Clonal hematopoiesis and blood-cancer risk.

Authors:  Giulio Genovese; Siddhartha Jaiswal; Benjamin L Ebert; Steven A McCarroll
Journal:  N Engl J Med       Date:  2015-03-12       Impact factor: 91.245

Review 3.  The evolving genomic landscape of myeloproliferative neoplasms.

Authors:  Jyoti Nangalia; Tony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

4.  Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.

Authors:  David A Hinds; Kimberly E Barnholt; Ruben A Mesa; Amy K Kiefer; Chuong B Do; Nicholas Eriksson; Joanna L Mountain; Uta Francke; Joyce Y Tung; Huong Marie Nguyen; Haiyu Zhang; Linda Gojenola; James L Zehnder; Jason Gotlib
Journal:  Blood       Date:  2016-06-30       Impact factor: 22.113

5.  Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

Authors:  Iñigo Martincorena; Amit Roshan; Moritz Gerstung; Peter Ellis; Peter Van Loo; Stuart McLaren; David C Wedge; Anthony Fullam; Ludmil B Alexandrov; Jose M Tubio; Lucy Stebbings; Andrew Menzies; Sara Widaa; Michael R Stratton; Philip H Jones; Peter J Campbell
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

6.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

7.  Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Authors:  William Tapper; Amy V Jones; Robert Kralovics; Ashot S Harutyunyan; Katerina Zoi; William Leung; Anna L Godfrey; Paola Guglielmelli; Alison Callaway; Daniel Ward; Paula Aranaz; Helen E White; Katherine Waghorn; Feng Lin; Andrew Chase; E Joanna Baxter; Cathy Maclean; Jyoti Nangalia; Edwin Chen; Paul Evans; Michael Short; Andrew Jack; Louise Wallis; David Oscier; Andrew S Duncombe; Anna Schuh; Adam J Mead; Michael Griffiths; Joanne Ewing; Rosemary E Gale; Susanne Schnittger; Torsten Haferlach; Frank Stegelmann; Konstanze Döhner; Harald Grallert; Konstantin Strauch; Toshiko Tanaka; Stefania Bandinelli; Andreas Giannopoulos; Lisa Pieri; Carmela Mannarelli; Heinz Gisslinger; Giovanni Barosi; Mario Cazzola; Andreas Reiter; Claire Harrison; Peter Campbell; Anthony R Green; Alessandro Vannucchi; Nicholas C P Cross
Journal:  Nat Commun       Date:  2015-04-07       Impact factor: 14.919

8.  Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis.

Authors:  Thomas McKerrell; Naomi Park; Thaidy Moreno; Carolyn S Grove; Hannes Ponstingl; Jonathan Stephens; Charles Crawley; Jenny Craig; Mike A Scott; Clare Hodkinson; Joanna Baxter; Roland Rad; Duncan R Forsyth; Michael A Quail; Eleftheria Zeggini; Willem Ouwehand; Ignacio Varela; George S Vassiliou
Journal:  Cell Rep       Date:  2015-02-26       Impact factor: 9.423

9.  Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion.

Authors:  David G Kent; Juan Li; Hinal Tanna; Juergen Fink; Kristina Kirschner; Dean C Pask; Yvonne Silber; Tina L Hamilton; Rachel Sneade; Benjamin D Simons; Anthony R Green
Journal:  PLoS Biol       Date:  2013-06-04       Impact factor: 8.029
  9 in total
  3 in total

Review 1.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Authors:  Elisa Rumi; Mario Cazzola
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

2.  JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics.

Authors:  Thomas McKerrell; Naomi Park; Jianxiang Chi; Grace Collord; Thaidy Moreno; Hannes Ponstingl; Joao Dias; Petroula Gerasimou; Kiki Melanthiou; Chrystalla Prokopiou; Marios Antoniades; Ignacio Varela; Paul A Costeas; George S Vassiliou
Journal:  Blood Adv       Date:  2017-06-12

Review 3.  Recent insights regarding the molecular basis of myeloproliferative neoplasms.

Authors:  Mi-Ae Jang; Chul Won Choi
Journal:  Korean J Intern Med       Date:  2019-11-29       Impact factor: 2.884
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.